The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial
Elbarbary, Nancy S; Ismail, Eman A; El-Hamamsy, Manal H; Ibrahim, Marwa Z; Elkholy, Amal A; elhamamsy, manal;
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibition has beneficial effects on various metabolic indicators in diabetes. Stromal cell-derived factor-1 (SDF-1) is expressed in diverse organs including the kidneys and is cleaved and inactivated by DPP-4 enzyme. The aim of this study was to conduct a randomised controlled trial to assess the effect of sitagliptin on diabetic nephropathy when used as an add-on therapy to the advanced hybrid closed-loop (AHCL) system in adolescents with type 1 diabetes and nephropathy.
Other data
| Title | The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial | Authors | Elbarbary, Nancy S; Ismail, Eman A; El-Hamamsy, Manal H; Ibrahim, Marwa Z; Elkholy, Amal A; elhamamsy, manal | Keywords | AHCL glucometrics; Diabetic nephropathy; Fasting lipids; MiniMed 780G; SDF-1; Sitagliptin; Type 1 diabetes | Issue Date | Dec-2024 | Publisher | Springer Nature | Journal | Diabetologia | Volume | 67 | Issue | December 2024 | Start page | 2637 | End page | 2649 | ISSN | 0012186X | DOI | 10.1007/s00125-024-06265-7 | PubMed ID | 39271520 | Scopus ID | 2-s2.0-85204108706 |
Attached Files
| File | Description | Size | Format | |
|---|---|---|---|---|
| s00125-024-06265-7.pdf | PDF Article | 1.43 MB | Unknown | View/Open |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.